Asthma affects 358 million people globally and, despite available therapies, many patients’ lives are still impacted by the disease.1,2 Uncontrolled asthma can cause a significant personal, health and financial burden to those living with it. Bertrand Bodson, the Chief Digital Officer of Novartis, has had asthma for over 10 years. He shares his experience of living with asthma, and how this drives his work at Novartis to reimagine medicine using the power of data and digital.

My journey with asthma

  • High-dose, once-daily Enerzair® Breezhaler® [IND/GLY/MF] reduced asthma exacerbation rates by 21% (moderate or severe) and 31% (severe) versus medium-dose, over 52 weeks1
  • Once-daily Enerzair Breezhaler, which includes an optional digital companion (sensor and app), is the first LABA/LAMA/ICS* fixed-dose combination approved for patients whose asthma is uncontrolled with a LABA/ICS2
  • Post hoc analysis complements findings from pivotal Phase III IRIDIUM study recently published …